Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.39 |
| ▸ | PIM1 | P11309 | 3/20 | 0.37 |
| ▸ | FPR2 | P25090 | 8/20 | 0.35 |
| ▸ | FPR1 | P21462 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249312 | 0.96 | PIM1 (0.38) | AKR1C3PIM1FPR2FPR1PIM3 | |
| SCHEMBL20249306 | 0.91 | PIM1 (0.43) | AKR1C3PIM1HSD11B1 | |
| SCHEMBL20038032 | 0.83 | PIM1 (0.41) | AKR1C3PIM1FPR2FPR1PIM3 | |
| SCHEMBL20038031 | 0.80 | PIM1 (0.39) | AKR1C3PIM1FPR2FPR1PIM3 | |
| SCHEMBL20037639 | 0.80 | AKR1C3 (0.39) | AKR1C3PIM1PIM3PIM2 | |
| SCHEMBL18291533 | 0.78 | PIM1 (0.41) | AKR1C3PIM1FPR2FPR1PIM3 | |
| SCHEMBL17207179 | 0.77 | AKR1C3 (0.50) | AKR1C3 | |
| SCHEMBL20249345 | 0.76 | CDK4 (0.43) | FPR2 | |
| SCHEMBL20249377 | 0.76 | SLC6A2 (0.55) | AKR1C3 | |
| SCHEMBL20255254 | 0.76 | PIM1 (0.40) | AKR1C3PIM1FPR2FPR1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | AKR1C3 2289/4885PIM1 596/4885FPR2 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.